I am an investor

I want to know more about Cantargia's research

I want to know more about Cantargia as a company

Presentation at ASCO 2019, follow up articles and interviews

Cantargia interview at EFN after ASCO

To the interview (in Swedish)

Cantargia partners up with pioneer within biotech industry

A brief introduction to Cantargia

To the interview

Two Nobel Prizes with utmost significance for Cantargia’s research

Press releases

2019-12-05 (R) Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis

2019-12-02 (R) Cantargia reports positive interim data from ongoing phase IIa combination study with antibody CAN04

2019-11-25 (R) Cantargia AB: Nomination Committee appointed ahead of 2020 Annual General Meeting

(R) = Regulatory press releases

”During 2018, we concluded the first very important part of the clinical development of CAN04 and presented patient data that strengthens our hopes that CAN04 can become an important part of tomorrow’s cancer treatment”

Göran Forsberg

CEO Cantargia

Analysis

2019-12-04, Nordea analysis of Cantargia

2019-12-03, Aktiespararna analysis of Cantargia (in Swedish)

2019-11-18 Nordea analysis of Cantargia

2019-11-04 Redeye analysis of Cantargia (in Swedish)

Presentations